IMP [OUTPERFORM +15.0%] - Strong growth prospects intact, led by hospital channel - Update
  • 2021-05-20T18:14:31
  • Company Research
We downgrade our rating from BUY to OUTPERFORM as IMP’s share price has rallied 35% in the last three months. That said, we lift our TP by 11% thanks to (1) a 50-bp decrease in our house cost of equity to 12.5% and (2) a rollover of our TP to mid-2022 vs YE2021 as previously.